Margaret Chu-Moyer

Margaret Chu-Moyer joined Amgen in 2009 and is currently head of Amgen’s Chemistry, Characterization, Technology & Externalization group, spanning Amgen’s research sites in Cambridge, MA, South San Francisco, CA and Thousand Oaks, CA. Her group encompasses medicinal chemistry, separation sciences, structure, biophysics, analytical sciences, materials management, high-throughput screening, research automation, bioassay and chemistry/biologics outsourcing, including a broad collaboration with Syngene in Bangalore, India. As part of the Therapeutic Discovery group that is responsible for delivering clinical candidates across all of Amgen’s various modalities – from monoclonal antibodies to peptides to small molecules – Margaret’s organization is accountable for advancing the small molecule portfolio across Amgen’s therapeutic research areas, namely Cardiometabolic Diseases, Inflammation, Oncology and Neuroscience. Margaret also held the role of Site Head for Amgen’s Cambridge, MA research facility from 2010 to 2014. Prior to joining Amgen, Margaret led both Medicinal Chemistry and Hit-To-Lead groups at Pfizer Global Research and Development in Groton, CT in the Cardiovascular, Metabolic and Endocrine Diseases therapeutic area. Margaret received her B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry from Yale University, in the area of natural products total synthesis. Margaret currently serves on the ACS Medicinal Chemistry Letters Editorial Advisory Board, the Bioorganic & Medicinal Chemistry and Bioorganic & Medicinal Chemistry Letters Editorial Advisory Board, the Boston Children’s Hospital Technology Development Fund Advisory Board, the American Cancer Society Cancer Drug Discovery Peer Review Committee and the UC Berkeley College of Chemistry Strategic Advisory Board.